MR 409
Based on 1 Customer Validation
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.98%
- CAS. Nr.: 1445155-39-4
- Formel: C153H252N44O43
- Molecular Weight:3395.91
-
Speicherung:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo[1].
MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)[2].
MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2[2].
MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner[3].
MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect[3].
MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect[3].
MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BPAEC
-
Concentration:1 μM
-
Incubation Time:24, 48 and 72 hours
-
Result:Significantly suppressed p53 expression levels after 48 and 72 hours of treatment.
MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)[3]
-
Dosage:5 µg
-
Administration:Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution
-
Result:Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.
Chemical Information
-
CAS. Nr. 1445155-39-4
-
Appearance Solid
-
Molecular Weight 3395.91
-
Formel C153H252N44O43
-
Color White to off-white
-
Sequence
{Asn-Me}-Tyr-{D-Ala}-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-{Orn}-Val-Leu-{Abu}-Gln-Leu-Ser-Ala-Arg-{Orn}-Leu-Leu-Gln-Asp-Ile-{Nle}-Asp-Arg-NHMe
-
Sequence Shortening
{N-Me}-Y-{D-Ala}-DAIFTNSYR-{Orn}-VL-{Abu}-QLSAR-{Orn}-LLQDI-{Nle}-DR-NHMe
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (29.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 50 mg/mL (14.72 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (288 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. [Content Brief]
[2]. Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7(4):1669989. [Content Brief]
[3]. Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11(1):2530. [Content Brief]
[4]. Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2109600118. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.2945 mL | 1.4724 mL | 2.9447 mL | 7.3618 mL |
| 5 mM | 0.0589 mL | 0.2945 mL | 0.5889 mL | 1.4724 mL | |
| 10 mM | 0.0294 mL | 0.1472 mL | 0.2945 mL | 0.7362 mL | |
| DMSO | 15 mM | 0.0196 mL | 0.0982 mL | 0.1963 mL | 0.4908 mL |
| 20 mM | 0.0147 mL | 0.0736 mL | 0.1472 mL | 0.3681 mL | |
| 25 mM | 0.0118 mL | 0.0589 mL | 0.1178 mL | 0.2945 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
MR 409 Related Classifications
HY-P3304 Related Classifications
Powered by Bioz